Takeda upgrades FY2026 outlook after 8.4% revenue growth
Key points
- Takeda Pharmaceutical (NYSE:TAK) reported first-half fiscal 2026 revenue growth of 8.4% at actual exchange rates, although revenue declined 1% at constant exchange rates.
- ORZEYFUL received approvals in the United States, Japan and China, MIMRYLO launched in the United States, and zasocitinib entered FDA Priority Review and European Medicines Agency review.
- Takeda raised its fiscal 2026 outlook to reflect foreign exchange benefits and plans to present further growth strategy details at its December 11, 2026, Capital Markets Day in Tokyo.
Takeda Pharmaceutical (NYSE:TAK) reported first-half fiscal 2026 revenue growth of 8.4% at actual exchange rates and upgraded its full-year outlook to reflect foreign exchange benefits.
Revenue declined 1% at constant exchange rates, while core operating profit increased 11.2% at actual exchange rates and 0.7% at constant exchange rates.
“The launches of ORZEYFUL and MIMRYLO, combined with the acceptance of zasocitinib under Priority Review and its positive head-to-head Phase 3 data, represent a significant moment for Takeda and reflect strong execution against our two-horizon growth strategy,” said Takeda President and Chief Executive Officer Julie Kim.
Reported operating profit rose 60.4% at actual exchange rates, core earnings per share increased 10.5% to ¥308, and adjusted free cash flow reached ¥325.7 billion.
ORZEYFUL received approvals in the United States, Japan and China for narcolepsy type 1, while MIMRYLO launched in the United States in August 2026 for erythrocytosis in polycythemia vera.
Takeda said the FDA accepted zasocitinib for Priority Review and the European Medicines Agency is reviewing the application, while the company plans to outline its growth strategy at a Capital Markets Day in Tokyo on December 11, 2026.
Frequently asked questions
More from United States
AB InBev Q3 revenue jumps 9.1% to $16.51 billion
ASE Technology posts 44.8% Q3 revenue growth to NT$244.2 billion
Magnum Ice Cream Q3 revenue rises 12.1% to €2.51 billion
Shell Q3 adjusted earnings rise to $10.8 billion
International Paper shares fall 6.6% as Q3 sales miss
UMC records NT$74.24 billion in Q3 revenue, up 25.6%
